Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1

Bibliography

• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev. 2013;33(Suppl 1):E1–E72.
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, De Clercq E, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem. 2012;55:3595–3613.
   PubMed Web of Science ®Google Scholar
• Chen X, Li Y, Ding S, et al. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. ChemMedChem. 2013;8:1117–1126.
   PubMed Web of Science ®Google Scholar
• Janssen PAJ, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine). J Med Chem. 2005;48:1901–1909.
   PubMed Web of Science ®Google Scholar
• Grammen C, Plum J, Van Den Brande J, et al. The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine. J Pharm Sci. 2014;103:3696–3703.
   PubMed Web of Science ®Google Scholar
• Bollini M, Frey KM, Cisneros JA, et al. Extension into the entrance channel of HIV-1 reverse transcriptase–crystallography and enhanced solubility. Bioorg Med Chem Lett. 2013;23:5209–5212.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Anderson KS. Novel compositions and methods of treating HIV-1 infections using same. US20140378443A1. 2014.
   Google Scholar
• Das K, Bauman JD, Clark AD Jr., et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA. 2008;105:1466–1471.
   PubMed Web of Science ®Google Scholar
• Morelock MM, Choi LL, Bell GL, et al. Estimation and correlation of drug water solubility with pharmacological parameters required for biological activity. J Pharm Sci. 1994;83:948–952.
   PubMed Web of Science ®Google Scholar
• Weuts I, Van Dycke F, Voorspoels J, et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J Pharm Sci. 2011;100:260–274.
   PubMed Web of Science ®Google Scholar
• Sun LQ, Qin B, Huang L, et al. Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett. 2012;22:2376–2379.
   PubMed Web of Science ®Google Scholar
• Huang B, Li C, Chen W, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. Eur J Med Chem. 2015;92:754–765.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Patents. 2014;24:1199–1227.
   PubMed Web of Science ®Google Scholar
• Hawley M, Morozowich W. Modifying the diffusion layer of soluble salts of poorly soluble basic drugs to improve dissolution performance. Mol Pharm. 2010;7:1441–1449.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin Ther Patents. 2011;21:717–796.
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Stoehr A, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother. 2010;54:3170–3178.
   PubMedGoogle Scholar
• Bollini M, Cisneros JA, Spasov KA, et al. Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility. Bioorg Med Chem Lett. 2013;23:5213–5216.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen W, Zhan P, et al. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur J Med Chem. 2014;87:52–62.
   PubMed Web of Science ®Google Scholar
• Huang B, Liang X, Li C, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. Eur J Med Chem. 2015;93:330–337.
   PubMed Web of Science ®Google Scholar
• Tian X, Qin B, Wu Z, et al. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem. 2010;53:8287–8297.
   PubMed Web of Science ®Google Scholar
• Qin B, Jiang X, Lu H, et al. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2010;53:4906–4916.
   PubMed Web of Science ®Google Scholar
• Sun LQ, Zhu L, Qian K, et al. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem. 2012;55:7219–7229.
   PubMed Web of Science ®Google Scholar
• Cho A. Recent advances in oral prodrug discovery. Annu Rep Med Chem. 2006;41:395–407.
   Google Scholar
• Lai M-T, Feng M, Falgueyret J-P, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58:1652–1663.
   PubMed Web of Science ®Google Scholar
• Cote B, Burch JD, Asante-Appiah E, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014;24:917–922.
   PubMed Web of Science ®Google Scholar
• Lee WG, Frey KM, Gallardo-Macias R, et al. Picomolar inhibitors of HIV-1 reverse transcriptase: design and crystallography of naphthyl phenyl ethers. ACS Med Chem Lett. 2014;5:1259–1262.
   PubMed Web of Science ®Google Scholar
• Frey KM, Puleo DE, Spasov KA, et al. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem. 2015;58:2737–2745.
   PubMed Web of Science ®Google Scholar